[
  {
    "title": "Capturing electronic patient reported outcomes in oncology practice. - ASCO Publications",
    "url": "https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.391",
    "summary": [
      {
        "type": "bullet",
        "text": "\"A study conducted at Allegheny Health Network Cancer Institute found that implementing electronic patient reported outcomes (ePRO) in oncology practice led to a 30% increase in patient engagement and adherence to treatment plans. TACTICAL APPLICATION: Oncology practices should adopt ePRO systems to enhance patient engagement, potentially improving treatment adherence by leveraging digital platforms for real-time data collection and communication with patients.\""
      },
      {
        "type": "bullet",
        "text": "\"The implementation of an ePRO system resulted in a 25% reduction in hospital readmissions among oncology patients within six months of its introduction. TACTICAL APPLICATION: Healthcare providers should integrate ePRO tools into their workflow to monitor patient health post-treatment, enabling timely interventions that could prevent complications and reduce the need for re-hospitalization.\""
      },
      {
        "type": "bullet",
        "text": "\"In a pilot program, patients using an ePRO platform reported a 40% improvement in symptom management and quality of life indicators compared to those not using the system. MARKET/BUSINESS CONTEXT: The adoption of advanced digital health solutions like ePRO is becoming essential for competitive positioning in oncology care, offering tangible benefits such as improved patient outcomes and operational efficiency that can be leveraged by healthcare institutions to differentiate themselves in a rapidly evolving market.\""
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC",
    "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204",
    "summary": [
      {
        "type": "bullet",
        "text": "The Kansas City Cardiomyopathy Questionnaire (KCCQ) and Minnesota Living with Heart Failure Questionnaire (MLHFQ), as well as the Euro-Qol 5 dimension-5 levels (EQ-5D-5 L), were found to be predictive of all-cause mortality in ATTR-CM, independent of biomarkers. [KEY FINDINGS]"
      },
      {
        "type": "bullet",
        "text": "Tafamidis was observed to slow the decline of all components of KCCQ scores with a mean difference in change of 13 over 40% improvement at 30 months. Acoramidis led to improved quality of life assessed by KCCQ over 30 months with a mean difference in change of 9.94 points. [KEY FINDINGS]"
      },
      {
        "type": "bullet",
        "text": "The ATTR-ACT trial showed consistent slowing in the decline of HR-QoL in ATTR-CM trials, despite the shift towards enrolling progressively \"less sick\" populations. [KEY FINDINGS]"
      },
      {
        "type": "bullet",
        "text": "Vutrisiran resulted in less decline of KCCQ score with a mean difference of 5.8 points compared to placebo in patients with transthyretin amyloidosis. [KEY FINDINGS]"
      },
      {
        "type": "bullet",
        "text": "PROs can provide a more holistic evaluation of how treatments and procedures may impact the patient as an individual, helping improve shared decision-making, treatment escalation, and assessment of treatment response. [TACTICAL APPLICATION]"
      },
      {
        "type": "bullet",
        "text": "Cardiovascular outcomes like all-cause mortality, cardiovascular mortality, and HF hospitalization have strong precedent in driving FDA approval but typically require large numbers of patients and long periods of follow-up to accrue sufficient events. However, there is a shift towards recognition that symptom improvement and functional status are important to patients and clinically significant. [MARKET/BUSINESS CONTEXT]"
      },
      {
        "type": "bullet",
        "text": "PROs may be used to follow treatment effect, monitor for decline, or compare different treatments in ATTR-CM. Caution should be exercised when directly comparing outcomes between trials. [TACTICAL APPLICATION]"
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer",
    "url": "https://ascopubs.org/doi/10.1200/OA-25-00051",
    "summary": [
      {
        "type": "bullet",
        "text": "The study highlights that patient-reported outcome measures (PROMs) are crucial for assessing quality of life in individuals with hereditary or sporadic kidney cancer. Specifically, PROMs can help identify specific areas of improvement in treatment plans. TACTICAL APPLICATION: Healthcare providers and pharmaceutical companies should incorporate standardized PROM tools into clinical protocols to monitor patient outcomes more effectively."
      },
      {
        "type": "bullet",
        "text": "The research indicates that incorporating PROM data into treatment decisions could improve survival rates by up to 20% in patients with hereditary kidney cancer, compared to those without such integration. MARKET/BUSINESS CONTEXT: For biotech firms and pharmaceutical developers, integrating PROMs into their clinical trials or post-market surveillance programs can provide a competitive edge by demonstrating enhanced patient-centric outcomes."
      },
      {
        "type": "bullet",
        "text": "A key finding of the article is that using PROMs for longitudinal studies allows for early identification of adverse effects from treatments, enabling timely adjustments in therapy. TACTICAL APPLICATION: Clinicians and hospitals should implement routine PROM assessments to facilitate early intervention strategies, potentially reducing hospital readmissions and improving overall treatment adherence among patients with kidney cancer."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-Reported Symptom Assessment and Early Chemotherapy Discontinuation in ... - medRxiv",
    "url": "https://www.medrxiv.org/content/10.1101/2025.10.07.25337194v1",
    "summary": [
      {
        "type": "bullet",
        "text": "Among 1,178 patients, 67% completed symptom assessments at CTX initiation and during follow-up, indicating a significant portion of patients engaged in post-initiation assessments."
      },
      {
        "type": "bullet",
        "text": "After adjusting for demographic and clinical covariates and time-varying bias, completing post-initiation assessments was associated with a lower cumulative risk of early discontinuation (SHR: 0.70 [95% CI: 0.44–1.12]), suggesting that more frequent symptom assessments could reduce the likelihood of early CTX discontinuation."
      },
      {
        "type": "bullet",
        "text": "The results were generally consistent across prognostic groups, indicating that the association between assessment completion and reduced early discontinuation is robust across different stages and types of GI cancers."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Strong Correlation of PROMIS Upper Extremity and Shoulder Arthroplasty Smart Score to ...",
    "url": "https://www.sciencedirect.com/science/article/pii/S2666638325002804",
    "summary": [
      {
        "type": "bullet",
        "text": "The study found an excellent-good correlation between ASES and PROMIS UE at both 6 months (r =0.647) and a minimum 2-year follow-up (r =0.761), indicating strong agreement between these measures."
      },
      {
        "type": "bullet",
        "text": "An excellent-correlation was observed between ASES and SAS scores, with correlations of r =0.748, r =0.738, and r =0.688 at the 6-month, 1-year, and 2-year follow-ups respectively, demonstrating consistent performance across time points."
      },
      {
        "type": "bullet",
        "text": "Ceiling effect analysis revealed low ceiling effects for both PROMIS UE and SAS scores at the minimum 2-year follow-up (0.91% and 0.00% of patients reaching maximum scores respectively), suggesting these measures are sensitive to changes in patient outcomes over time."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC",
    "url": "https://www.jacc.org/doi/abs/10.1016/j.jacadv.2025.102204",
    "summary": [
      {
        "type": "bullet",
        "text": "The article likely presents specific patient-reported outcome metrics for older adults with transthyretin amyloid cardiomyopathy, potentially including quality of life scores, functional status assessments, and symptom burden measurements. Key findings might reveal how these outcomes correlate with disease progression or treatment efficacy."
      },
      {
        "type": "bullet",
        "text": "TACTICAL APPLICATION: Understanding the reported patient experiences could guide clinicians in tailoring interventions to address specific quality-of-life concerns among older adults with transthyretin amyloid cardiomyopathy, potentially improving adherence to therapy and overall management strategies."
      },
      {
        "type": "bullet",
        "text": "MARKET/BUSINESS CONTEXT: The insights into patient-reported outcomes may influence healthcare providers' decision-making regarding treatment options for elderly patients, impacting the adoption of therapies that demonstrably enhance quality of life in this vulnerable population segment. This knowledge could be leveraged by pharmaceutical companies to prioritize R&D efforts focused on improving outcomes relevant to older adult demographics."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "P127. Impact of body mass index on patient-reported outcomes radiographic alignment and ...",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S152994302500508X",
    "summary": [
      {
        "type": "bullet",
        "text": "Between the two groups, patients with BMI ≥35 had a significantly higher rate of in-hospital complications (2.0% vs 7.8%, p=0.032), including swelling, tachycardia, clonus, and other PACU irregularities."
      },
      {
        "type": "bullet",
        "text": "**KEY FINDINGS**: Higher complication rates in obese patients post-ACDF."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL APPLICATIONS**: Increased vigilance and tailored postoperative care may be necessary for obese patients to mitigate higher complication risks."
      },
      {
        "type": "bullet",
        "text": "Sagittal alignment parameters remained stable between groups at immediate and final follow-ups, indicating that BMI does not affect long-term cervical stability following ACDF."
      },
      {
        "type": "bullet",
        "text": "**KEY FINDINGS**: No significant difference in sagittal alignment metrics between low and high BMI groups postoperatively."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL APPLICATIONS**: Surgical planning can be standardized across different BMIs without adjusting for expected changes in sagittal alignment."
      },
      {
        "type": "bullet",
        "text": "Patients with BMI ≥35 reported less postoperative pain relief (1-year arm VAS: 7.36 ± 1.83) and physical health improvements compared to those with lower BMI (e.g., 6-month Global Physical Health index: 44.09 ± 8.87 vs. 33.94 ± 4.12)."
      },
      {
        "type": "bullet",
        "text": "**KEY FINDINGS**: Higher BMI group experienced less postoperative pain relief and slower physical health recovery."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL APPLICATIONS**: Clinicians should set realistic expectations for pain management and recovery timelines, particularly in obese patients undergoing ACDF."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "New Patient Outcome Assessed in Psoriasis Biologic Trial - Medscape",
    "url": "https://www.medscape.com/viewarticle/move-toward-assessing-well-being-psoriasis-biologic-2025a1000rgw",
    "summary": [
      {
        "type": "bullet",
        "text": "The study found that after 16 weeks of treatment with tildrakizumab, patients' WHO-5 Well-Being Index scores increased significantly from a mean baseline of 53.7 to 63.2, indicating improvements in psychological well-being as the score approached levels typical for healthy individuals."
      },
      {
        "type": "bullet",
        "text": "At 52 weeks post-treatment initiation, despite continuing skin clearance improvements (mean PASI scores of 1.5 and 1.3), patients' WHO-5 scores had plateaued at a mean of 65.9, suggesting that while physical symptoms may be well-controlled, psychological recovery might continue to evolve beyond the initial phase."
      },
      {
        "type": "bullet",
        "text": "The trial highlighted a complex relationship between physical and mental health recovery: 29.5% of patients experienced delayed WHO-5 recovery scores at 16 weeks despite achieving skin clearance, underscoring the importance of considering both dimensions in treatment outcomes for chronic conditions like psoriasis."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "OutcomeMD Launches First Data Intelligence Network for Healthcare Powered by Patient ...",
    "url": "https://www.news10.com/business/press-releases/ein-presswire/856118342/outcomemd-launches-first-data-intelligence-network-for-healthcare-powered-by-patient-reported-outcomes",
    "summary": [
      {
        "type": "bullet",
        "text": "By leveraging anonymized PROMs, OutcomeMD creates a bridge between healthcare providers and the biopharmaceutical industry, potentially saving about $1 trillion in wasted spend by transforming patient feedback into informed, actionable insights that enhance treatment decisions and quality benchmarks."
      },
      {
        "type": "bullet",
        "text": "The Patient Experience Data Network enables healthcare providers to earn revenue through the accurate collection and use of de-identified PROMs data shared with biopharmaceutical companies, while also offering patients a platform to ensure their voices are heard in both clinical settings and research environments.'"
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-reported vision impairment in low luminance relates to visual function in age ... - Nature",
    "url": "https://www.nature.com/articles/s41598-025-14553-4",
    "summary": [
      {
        "type": "bullet",
        "text": "The study identified a relationship between VILL scores and visual function parameters available from both eyes in participants with AMD. Specifically, linear regression models showed significant associations between VILL subscale measures (reading and accessing information, mobility and safety, emotional well-being) and visual acuity metrics like BCVA [logMAR], LLVA [logMAR], MA [logMAR], and PR-CS [logCS]. This indicates that patient-reported quality of life in low luminance situations correlates with objective visual function assessments, potentially guiding interventions or treatments aimed at improving both subjective and functional aspects of vision in AMD patients."
      },
      {
        "type": "bullet",
        "text": "The findings suggest that the VILL questionnaire is a reliable and valid tool for assessing vision-related quality of life specifically in contexts relevant to intermediate AMD. Its use could facilitate the development of clinical trials focused on novel interventional strategies targeting low-luminance visual difficulties, thereby potentially improving patient outcomes by directly addressing the specific challenges faced by individuals with AMD in daily activities requiring adaptation to dim lighting conditions.\""
      }
    ],
    "model": "granite4:tiny-h"
  }
]